These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 7912565)

  • 1. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy.
    Nicholson RI; McClelland RA; Gee JM; Manning DL; Cannon P; Robertson JF; Ellis IO; Blamey RW
    Breast Cancer Res Treat; 1994 Jan; 29(1):117-25. PubMed ID: 7912565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
    Archer SG; Eliopoulos A; Spandidos D; Barnes D; Ellis IO; Blamey RW; Nicholson RI; Robertson JF
    Br J Cancer; 1995 Nov; 72(5):1259-66. PubMed ID: 7577479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.
    Nicholson RI; McClelland RA; Finlay P; Eaton CL; Gullick WJ; Dixon AR; Robertson JF; Ellis IO; Blamey RW
    Eur J Cancer; 1993; 29A(7):1018-23. PubMed ID: 8098946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy.
    Gee JM; Robertson JF; Ellis IO; Willsher P; McClelland RA; Hoyle HB; Kyme SR; Finlay P; Blamey RW; Nicholson RI
    Int J Cancer; 1994 Dec; 59(5):619-28. PubMed ID: 7960234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical studies on oncogene products (EGF-R, c-erbB-2) and growth factors (EGF, TGF-alpha) in human breast cancer: their relationship to oestrogen receptor status, histological grade, mitotic index and nodal status.
    Umekita Y; Enokizono N; Sagara Y; Kuriwaki K; Takasaki T; Yoshida A; Yoshida H
    Virchows Arch A Pathol Anat Histopathol; 1992; 420(4):345-51. PubMed ID: 1348890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu.
    Harris AL; Nicholson S; Sainsbury JR; Farndon J; Wright C
    J Steroid Biochem; 1989; 34(1-6):123-31. PubMed ID: 2576295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor-alpha and endocrine sensitivity in breast cancer.
    Nicholson RI; McClelland RA; Gee JM; Manning DL; Cannon P; Robertson JF; Ellis IO; Blamey RW
    Cancer Res; 1994 Apr; 54(7):1684-9. PubMed ID: 8137282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
    Wright C; Nicholson S; Angus B; Sainsbury JR; Farndon J; Cairns J; Harris AL; Horne CH
    Br J Cancer; 1992 Jan; 65(1):118-21. PubMed ID: 1346366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
    Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A
    J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor status, proliferating activity, and c-erbB2 oncoprotein. An immunocytochemical evaluation in breast cancer.
    Campani D; Sarnelli R; Fontanini G; Martini L; Cecchetti D; De Luca F; Squartini F
    Ann N Y Acad Sci; 1993 Nov; 698():167-73. PubMed ID: 7904137
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunohistochemical expression of c-erbB-2 oncoprotein and EGF-R in pre- and postmenopausal breast cancer.
    Ratnakar N; Sharma BK; Chaturvedi KU; Kaur S; Naik SL; Ray A
    APMIS; 1998 Nov; 106(11):1075-80. PubMed ID: 9890270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
    Gasparini G; Boracchi P; Bevilacqua P; Mezzetti M; Pozza F; Weidner N
    Breast Cancer Res Treat; 1994 Jan; 29(1):59-71. PubMed ID: 7912568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen.
    Gilhus NE; Jones M; Turley H; Gatter KC; Nagvekar N; Newsom-Davis J; Willcox N
    J Clin Pathol; 1995 May; 48(5):447-55. PubMed ID: 7629292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer.
    Manning DL; McClelland RA; Gee JM; Chan CM; Green CD; Blamey RW; Nicholson RI
    Eur J Cancer; 1993; 29A(10):1462-8. PubMed ID: 8398276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.
    Robertson JF; Bates K; Pearson D; Blamey RW; Nicholson RI
    Br J Cancer; 1992 May; 65(5):727-30. PubMed ID: 1534019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.
    Shimizu D; Ishikawa T; Tanabe M; Sasaki T; Ichikawa Y; Chishima T; Endo I
    Breast Cancer; 2014 Sep; 21(5):557-62. PubMed ID: 23184499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of epidermal growth factor receptor in breast cancer, from early stages to advanced disease.
    Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Branković-Magić M; Kanjer K; Gavrilović D; Mitrović L; Borojević N; Vukotić D; Spuzić I
    J Exp Clin Cancer Res; 1999 Sep; 18(3):347-55. PubMed ID: 10606181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study.
    Klijn JG; Look MP; Portengen H; Alexieva-Figusch J; van Putten WL; Foekens JA
    Breast Cancer Res Treat; 1994 Jan; 29(1):73-83. PubMed ID: 8018964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
    Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
    Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between epidermal growth factor receptor (EGF-R) and other predictors of prognosis in breast carcinomas. An immunohistochemical study.
    Martinazzi M; Crivelli F; Zampatti C; Martinazzi S
    Pathologica; 1993; 85(1100):637-44. PubMed ID: 8170712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.